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REVIEW
Abstract: Alendronate is one of the best and most extensively studied bisphosphonates in
the treatment of osteoporosis. This review considers in detail the major pivotal study, the
fracture intervention trial (FIT), upon which the use of alendronate is based and which was a
landmark study in terms of design, size and clinical impact. The role of alendronate has
subsequently been underscored by a range of studies extending the clinical indications for its
use and consolidating the effect on reducing both vertebral and non-vertebral fracture risk.
Although the emphasis of these studies has predominantly been on the management of
postmenopausal osteoporosis, data is also available in primary prevention, men, and
glucocorticoids-induced osteoporosis. Direct comparison between the different drugs used to
treat osteoporosis with fracture end points are needed for patients and doctors to make informed
choices, but the size of such studies are prohibitive. Clinical trials using surrogate markers
such as bone mineral density and biochemical markers of bone turnover have been performed
which provide some helpful information but the limitations of this approach need to be
recognized.
Keywords: alendronate, osteoporosis, hormone replacement therapy, male osteoporosis,
parathyroid hormone, corticosteroid-induced osteoporosis
Introduction
Alendronate is one of the best and most extensively studied bisphosphonates in the
treatment of osteoporosis. The fracture intervention trial (FIT) was a landmark study
in terms of design, size, and clinical impact. The role of alendronate has subsequently
been underscored by a range of studies extending the clinical indications for its use
and consolidating the effect on reducing both vertebral and non-vertebral fracture
risk.
Pivotal studies
A quartet of pivotal studies formed the basis for the subsequent clinical trials of
alendronate and for post hoc analyses (Liberman et al 1995; Black et al 1996, 2000;
Cummings et al 1998). The first of these examined the dose-response relationship in
terms of gain in bone mineral density (BMD) and fracture risk reduction but a more
extensive study of the effect on fractures was the central feature of the Fracture
Intervention Trial (FIT). They will be considered in detail since they are of such
importance to the subsequent use of alendronate in the treatment of osteoporosis.
Alendronate dose-response (Liberman et al 1995)
One of the great strengths of the alendronate clinical research programme was the
early demonstration of a clear dose-response relationship and the identification of
10 mg daily as the optimal dose in terms of the gain in BMD. In this trial, 994 women
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with postmenopausal osteoporosis (lumbar spine BMD T
Score <−2.5), of whom about 20% had a prevalent vertebral
fracture, were randomized to placebo, 5 mg or 10 mg daily
for three years, or 20 mg daily for two years, and then 5 mg
daily for the third year. It was a well conducted investigation
with 91% of the women completing a year of the study and
paired spine films being available on 97%. After 3 years,
the 10 mg dose had increased lumbar spine BMD by 8.8%
relative to placebo with increments of 5.9% and 7.8% at the
femoral neck and trochanteric area of the hip with a gain of
2.5% at the total body and 2.2% at the mid forearm (p<0.001
for all comparisons). The 10 mg dose was significantly more
effective than the 5 mg dose at all skeletal sites, but was as
effective as the 20 mg dose. Most of the gain in BMD
occurred in the first 6 months of treatment but was
independent of the baseline value.
The relative risk (RR) of a new morphometric fracture
among women treated with alendronate (all doses
combined) compared with placebo was 0.52 (95%
confidence index [CI] 0.28–0.95). Interestingly the
protective effect was independent of alendronate dose,
presence of a previous vertebral fracture or age >65 years.
Multiple vertebral fractures were also reduced, although
absolute numbers were small. The Spinal Deformity
Index (SDI) an aggregate of vertebral deformity showed
a similar pattern of response with protection afforded by
alendronate but of marginal statistical significance
(p=0.054). Alendronate also reduced the risk of height
loss by 35% which was more marked in women ≥65 years
and in those with a prevalent fracture. There was no effect
on height loss in women without a new vertebral fracture,
but in those with a new vertebral fracture, alendronate
reduced height loss (placebo: 23.3 mm, alendronate:
5.9 mm). This latter effect represents the action of
alendronate to decrease the number and severity of wedge
and crush fractures. There was a trend towards a reduction
in non-vertebral fractures but this did not reach statistical
significance (RR 0.79, 95% CI 0.52–1.22) and since this
was a post-hoc analysis it requires caution in
interpretation. Alendronate was well tolerated with no
excess of drug-related withdrawals, severe adverse
events, or discontinuation due to upper gastrointestinal
effects.
This was an important study of patients who were not
selected because they were at high risk of fractures and who
were probably more representative of the usual clinic
population.
FIT: vertebral fracture arm (Black et al
1996)
The FIT comprised two studies with the pre-specified aim
that the combination would be analyzed as well as the
individual arms. The first study to be reported included 2027
women aged 55–81 years with a prior vertebral fracture and
a femoral neck BMD <0.68 g/cm
2, considered to be
equivalent to a value of 2.1 standard deviations (SD) below
the young normal peak BMD (T score). Subsequent to the
start of FIT the results from the Third National Health and
Nutrition Examination Survey (Looker et al 1995) had
shown that the BMD inclusion criteria corresponded to a T
score of –1.6, much higher than the intended value of –2.1
but still consistent with a diagnosis of osteoporosis in women
with a prior vertebral fracture. Study subjects were
randomized either to alendronate (1022) or placebo
(1005).The alendronate dose was 5 mg daily for the first
two years and then 10 mg/day after the Phase III study
(Liberman et al 1995) showed the superiority of the larger
dose in terms of gain in BMD and reduction in bone
turnover. A history of (any) fracture since the age of 45 years
was given by 58% of the placebo group and 57% of those
given alendronate. Calcium intake was assessed by food
frequency questionnaire and those with an intake <1 g/day
(82%) were given supplements of 500 mg calcium and
250IU vitamin D. The primary end point of the trial was a
new morphometric vertebral fracture defined as a reduction
of 20% (and at least 4 mm) in either anterior, mid, or
posterior vertebral height between baseline and last follow
up visit. Secondary end points included any clinical fractures
and loss of height. Clinical fractures were defined as one
diagnosed by a physician while self-reported fractures were
confirmed by a written radiographic report or other tests.
The trial entrants were predominantly (97%) Caucasian and
spine radiographs were obtained at the close out visit in
1949 out of 2027 patients. At the close out visit, 90% of the
women were still taking the trial medication and 96% of
them had taken >75% of their pills since the previous visit.
This was a very well conducted trial, providing good quality
fracture data.
The results are summarized in Table 1 but included a
47% reduction in morphometric fractures (primary end
point), a 55% reduction in clinical vertebral fractures and a
28% reduction in clinical spine and non-spine fractures
(main secondary end point). These effects were independent
of baseline BMD. There was not a significant reduction in
all non-spine fractures although wrist and hip fractures wereTherapeutics and Clinical Risk Management 2006:2(3) 237
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significantly reduced as was height loss. The gain in BMD,
relative to placebo, was similar to that seen in the Phase III
study and was 6.2% at the lumbar spine, 4.1% at the femoral
neck, 4.7% at the total hip, 6.1% at trochanter, 1.8% at total
body, and 1.6% at proximal forearm.
Adverse events including those arising from the upper
gastrointestinal tract (placebo 2.2%, alendronate 1.6%) were
similar between alendronate and placebo and this was also
true in the third year when the alendronate dose was
increased from 5 mg to 10 mg daily. There was no excess of
adverse events in either group in women taking concomitant
non-steroidal anti-inflammatory drugs.
FIT: clinical fracture arm (Cummings et
al 1998)
Two years later the effects of alendronate on fracture risk in
postmenopausal women with a low BMD, but no vertebral
fracture was reported in 4432 women aged 54–81 years with
a femoral neck BMD <0.68 g/cm2. As discussed above, the
Third National Health and Nutrition Examination Survey
(NHANES III) (Looker et al 1995) had shown that the BMD
inclusion criteria corresponded to a T score of –1.6 rather
than the intended value of –2.1. A total of 2218 women
were randomized to placebo and 2214 to alendronate and
followed for an average of 4.2 years. Although the entry
requirement was the absence of a prior vertebral fracture,
35% of those receiving placebo and 36% given alendronate
had a history of a non-spine fracture since the age of 45
years which was about 20% less than that seen in the
vertebral fracture study. Otherwise the two trial protocols
were identical, including the increase in alendronate dose
at two years, the provision of calcium and vitamin D
supplements, compliance with trial medication and the
completeness of data acquisition.
The gain in BMD at 4 years with alendronate relative to
placebo (bone gain with treatment + bone loss with placebo)
was similar to previous studies: lumbar spine 6.6%, femoral
neck 4.6%, trochanter 6.8%, total hip 5.0%, total body 2.0%,
and ultra-distal radius 3.1%. The increase in BMD was
independent of baseline BMD. Although alendronate
reduced the risk of most types of fracture by about 12%–
21% none of these changes were significant (Table 2). The
exceptions were morphometric vertebral fractures and “other
clinical fractures” (which excluded clinical fractures of
spine, hip and wrist) but showed a 21% reduction relative
hazard (RH) 0.79, 95% CI 0.65-0.96). The risk of wrist
fractures appeared to increase. The effect of treatment was
dependent on baseline BMD so that it was only patients
with a femoral neck BMD below –2.5 based on NHANES
III (lowest tertile) who showed a significant protective effect.
Table 1 Fracture risk in postmenopausal women with a prevalent vertebral fracture*
Fracture type Placebo (%) Alendronate (%) Fracture risk (95% CI)
Morphometric ≥1 145 (15) 78 (8) 0.53 (0.41–0.68)
Morphometric ≥−2 47 (4.9) 5 (0.5) 0.10 (0.05–0.22)
Clinical vertebral 50 (5.0) 23 (2.3) 0.45 (0.27–0.72)
Any clinical 183 (18.2) 139 (13.6) 0.72 (0.58–0.90)
Any non-vertebral 148 (14.7) 122 (11.9) 0.80 (0.63–1.01)
Hip 22 (2.2) 11 (1.1) 0.49 (0.23–0.99)
Wrist 41 (4.1) 22 (2.2) 0.52 (0.31–0.87)
Height loss (mm) 9.3 6.1 p<0.001
Note: * Black et al 1996.
Abbreviations: CI, confidence interval.
Table 2 Fracture risk in postmenopausal women without a prevalent vertebral fracture*
Fracture type Placebo (%) Alendronate (%) Fracture risk (95% CI)
Morphometric ≥1 78 (3.8) 43 (2.1) 0.56 (0.39–0.80)
Morphometric ≥2 10 (0.5) 4 (0.2) 0.40 (0.13–1.24)
Clinical vertebral**
Any clinical 312 (14.1) 272 (12.3) 0.86 (0.73–1.01)
Any non-vertebral 294 (13.3) 261 (11.8) 0.88 (0.74–1.04)
Hip 24 (1.1) 19 (0.9) 0.79 (0.43–1.44)
Wrist 70 (3.2) 83 (3.7) 1.19 (0.87–1.64)
Height loss (mm) 8.5 7.0 p<0.001
Note: *Cummings et al 1998, **Clinical vertebral fractures included in “any clinical” fractures.
Abbreviations: CI, confidence interval.Therapeutics and Clinical Risk Management 2006:2(3) 238
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In this subgroup, clinical fractures were reduced by 36%
(RH 0.64; 95% CI 0.50–0.82), hip fractures by 56% (RH
0.44; 95% CI 0.18–0.97) and morphometric spine fractures
by 50% (RH 0.50; 95% CI 0.31–0.82), but there was no
reduction in wrist fractures. Adverse events were similar
between placebo and alendronate as had been found
previously.
This study shows an interesting contrast between the
gain in BMD which was independent of starting value and
the reduction in fracture risk which was strongly influenced
by a BMD below –2.5. This is consistent with an effect of
alendronate reducing the size of the remodelling space in
patients with thinned trabeculae as shown by the low BMD
(Heaney et al 1997). The importance of reducing the first
fracture with anti-resorptive therapy is the hope that it will
reduce the risk of future fractures which is strongly
influenced by the first event (Klozbuecher et al 2000).
FIT: osteoporotic cohort (Black et al
2000)
The observation from the previous study that fracture risk
reduction only occurred in about a third of the cohort (1631/
4438) with osteoporosis, as shown by a femoral neck T score
below –2.5, reinforced the need which had been pre-
specified in the FIT data analysis plan to compare and pool
the osteoporotic women in the two arm of FIT. Before
pooling studies, it is necessary to show the homogeneity of
the odds ratio with treatment and this was confirmed by the
Breslow–Day test. The baseline characteristics of the two
groups were similar except that the women without vertebral
fractures were about 2 years younger, less likely to have
had a non-spine fracture since age 45 years, but had a lower
hip (but not spine) BMD. Vertebral and non-vertebral
fracture rates were higher in the women with a prior vertebral
fracture as would be expected (Klozbuecher et al 2000).
The aim of combining all the women in the vertebral fracture
arm (2027) with those in the clinical fracture arm with a
femoral neck T score below –2.5 (1631) was to construct a
larger cohort. This provided the opportunity to examine the
effect of treatment on subgroups, the time course of these
changes, and provide greater power to examine associations
between variables. This was a true intention-to-treat analysis
since all events after randomization were included.
The point estimates of the reduction in fracture risk
(Table 3) were similar for those with and without a prevalent
spine fracture and there was no significant heterogeneity in
the relative risks between the two groups for any type of
fracture. When the two groups were combined there was a
significant reduction in all major fracture types varying from
27%–87% and the pattern and magnitude of change was
similar whether osteoporosis was defined in terms of total
hip or lumbar spine BMD. All fracture types showed some
reduction of risk in the first year. They became significantly
different from placebo by 12 months for clinical vertebral
fractures (59%), by 18 months for any clinical fracture (27%)
and hip fractures (63%), by month 24 for non-vertebral
fractures (26%) and by month 30 for wrist fractures (30%).
These pivotal trials have been further analyzed and extended
by additional studies to cover several practical aspects of
the long term therapy for osteoporosis.
Supporting studies
Non-spine fractures
Additional as well as supportive evidence as to the efficacy
of alendronate was provided by the multinational Fosamax
International Trial (FOSIT) (Pols et al 1999) where 1908
patients with a T score of –2 or less were treated for a year
with 10 mg daily or placebo. All participants were
supplemented with 500 mg calcium but no vitamin D. The
primary end point was the change in BMD but non-spine
Table 3 Fracture risk in osteoporotic postmenopausal cohort*
Fracture type  Vertebral Fx Arm Clinical Fx Arm Osteoporotic
RR (95% CI)  (T < –2.5) cohort
RR (95% CI) RR (95% CI)
Morphometric ≥1 0.53 (0.41–0.68) 0.51 (0.31–0.84) 0.52 (0.42–0.66)
Morphometric ≥2 0.10 (0.05–0.22) 0.40 (0.08–1.95) 0.13 (0.07–0.25)
Clinical vertebral 0.46 (0.28–0.75) 0.84 (0.38–1.83) 0.55 (0.36–0.82)
Any clinical 0.74 (0.59–0.92) 0.64 (0.50–0.82) 0.70 (0.59–0.82)
Any non-vertebral 0.81 (0.64–1.03) 0.65 (0.50–0.83) 0.73 (0.61–0.87)
Hip 0.49 (0.23–0.99) 0.44 (0.18–0.97) 0.47 (0.26–0.79)
Wrist 0.52 (0.31–0.87) 0.88 (0.55–1.40) 0.70 (0.49–0.90)
Note: *Black et al 2000.
Abbreviations: CI, confidence interval; Fx, fracture; RR, relative risk.Therapeutics and Clinical Risk Management 2006:2(3) 239
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fractures were captured as an adverse event. Spine films
were not performed at baseline and so the exact fracture
risk status of the participants is not known, preventing direct
comparison with FIT. At 12 months the gain in BMD with
alendronate relative to placebo was 4.9% at lumbar spine,
2.4% at femoral neck, 3.6% at trochanter and 3.0% at total
hip. These gains were similar to those seen in the dose
response study (Liberman et al 1995)
 and were accompanied
by a 52% decrease in bone specific alkaline phosphatase
(BSAP) and a 74% decrease in urine N terminal propeptide
of type 1 collagen (NTx). At the end of a year, 37/958 (4.4%)
of the patients treated with placebo had experienced a non-
spine fracture while the comparable figures for the
alendronate group were 19/950 (2.4%) representing a 47%
reduction in risk (RH 0.53, 95% CI 0.30–0.90).
This study is important because of the rapidity of the
protection against non-spine fractures, probably partly due
to the use of the optimal 10 mg dose of alendronate from
the outset. It was also an important confirmation of the
consistency of alendronate effect since the study was
composed of a wide variety of racial groups and yet changes
in BMD, bone turnover, and fracture protection were similar
to those of earlier more homogeneous studies.
High risk groups
The vertebral fracture arm of FIT was re-analysed to explore
the extent alendronate is able to reduce the fracture risk of
the most vulnerable women (Ensrud et al 1997). In the study
as a whole, the protective effect against both new vertebral
and new clinical fractures was consistent across categories
defined by age (<75 years, ≥75 years), median femoral neck
BMD (<0.59g/cm
2, ≥0.59 g/cm
2), history of postmenopausal
fracture (yes/no) and number of prevalent fractures (1
vertebral fracture, ≥2 vertebral fractures). The practical
implication of these findings is that they show that more
fractures will be prevented by treating those women at
highest risk defined by advanced age, low BMD, and
multiple previous fractures.
Prevention of multiple fractures
The effect of alendronate on multiple symptomatic fractures
was assessed from an intention to treat (ITT) analysis of the
osteoporotic cohort of 3658 postmenopausal women in FIT
(Levis et al 2002).
Most trials of osteoporosis censor (remove from further
analysis) patients once they have had a fracture but there
are obvious attractions to analyzing all events. Not only are
multiple fractures of clinical importance but the greater the
number of events available for analysis, then the impression
of the effects of therapy are more complete.
However, because the first fracture increases the risk of
subsequent events, the statistical analysis must adjust for
the increase in risk of subsequent fractures due to the
occurrence of the initial event. An addition attraction of this
approach is that the number of events which contribute to
the clinical outcome is increased, in this instance by 32%,
compared with trials which evaluate of the risk of first
fracture after which the patient is censored from further
analysis. There were 789 symptomatic fractures in the 4
year follow up with 86 multiple fractures in 1817 women
treated with placebo and 51 fractures in 1841 women treated
with alendronate. This equates to a relative risk reduction
of multiple symptomatic fractures with alendronate of 42%
(RR 0.58, 95% CI 0.41–0.81). Comparable effects on
multiple vertebral fractures were RR 0.16 (95% CI 0.05–
0.42) and on three or more fractures was RR 0.25 (95% CI
0.10–0.55) although the absolute number of the latter was
very small. About half the patients with multiple
symptomatic fractures had a prevalent vertebral fracture.
The effect of alendronate became statistically significant at
6 months for multiple symptomatic vertebral fractures and
at 12 months for multiple spine and non-spine symptomatic
fractures. The reductions in risk occurred independent of
age, prior morphometric or clinical vertebral fracture or the
presence of a fall in the previous year.
It was also possible to examine the entire fracture
experience of the osteoporotic cohort in terms of the first
fracture in those with a low BMD as well as subsequent
fractures in those who entered FIT with a prevalent
fracture. Alendronate reduced the risk of a symptomatic
fracture by 34% (RR 0.66, 95% CI 0.57–0.77) and
symptomatic vertebral fractures by 63% (RR 0.37, 95%
CI 0.26–053) which is greater than the equivalent
reductions of 30% and 45% based on first fracture only
(Table 3). The results were the same when the whole
cohort of 6459 women in FIT were subjected to the same
statistical analysis although the benefits of alendronate
were diluted by the women at low fracture risk because
they were osteopenic without a prior fracture. The ability
to prevent multiple fractures may alter the long term
course of the disease since another analysis of FIT showed
that the risk of future vertebral fractures increased with
the number of prevalent fractures independent of age and
BMD
 (Nevitt et al 1999). The ability of alendronate to
attenuate this risk was not affected by the number or
location of these prevalent fractures.Therapeutics and Clinical Risk Management 2006:2(3) 240
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Predicting responses
Since osteoporosis is a chronic condition requiring long term
treatment, there is a real need to be able to monitor and
predict response as well as to motivate patients to comply
with treatment. Increased bone turnover is a well recognized
predictor of fracture risk (Garnero et al 1996, 2000)
 and
since substantial changes occur rapidly in response to potent
inhibitors of bone turnover they have obvious application
to the evaluation of therapy. Short term changes over 6
months in bone turnover markers, particularly urine NTx,
were able to predict the gain in BMD at spine, hip, and total
body at 24 months in elderly calcium and vitamin D
supplemented women treated with either placebo or
alendronate 5 mg daily for the first year and then 10 mg daily
for the second year (Greenspan et al 1998). In this study,
which was not powered for anti-fracture effect, the gains in
BMD were similar to those seen in FIT. Only baseline NTx
correlated with the gain in BMD and this was consistent
with earlier reports (Bone et al 1997), but the change in all
the markers, which comprised urine NTx and free
deoxypyridinoline (Dpd), osteocalcin, and BSAP, at 6
months were predictive of gain in BMD. Only NTx and
osteocalcin were predictive of gain at all measurement sites.
Those with the largest decrease in NTx showed the biggest
gains in BMD so that a 30% decrease in NTx predicted
gains in BMD of 5.8% at lumbar spine, 4.1% at trochanter,
and 2.8% at the total hip at 2.5 years. The indirect assumption
is that the greater the gain in BMD, the greater the reduction
in fracture risk (Wasnich and Miller 2000; Hochberg et al
2002).
More recently, data from FIT has been analyzed to
establish whether there is an association between the change
in bone turnover and the reduction in fracture risk (Bauer et
al 2004). As would be expected, baseline hip BMD was
associated with future fracture risk but baseline bone
turnover markers were not correlated with any type of
fracture outcome. The magnitude of the change in bone
turnover over the first 12 months of alendronate therapy
did predict the effect on spine, non-spine, and hip fractures.
BSAP proved to be the most predictive and while serum N-
terminal propeptide of type 1 collagen (PINP) and serum
C-terminal crosslinked telopeptide of type 1 collagen (CTx)
were associated with a reduction in spine fractures, they
only showed similar, but nonsignificant, associations with
hip and non-spine fractures. In an age-adjusted logistic
regression model, a 1 SD reduction in BSAP was associated
with a 26% reduction in spine fractures (CI 13%–37%), an
11% reduction in non-spine fractures (CI 0%–22%) and a
39% reduction in hip fractures (CI 22%–54%). The
relationship between % change in bone turnover and
reduction in fracture risk persisted after adjustment for
change in spine BMD and did not differ when absolute
changes in bone turnover were used. The results were also
similar when analyses were restricted to women with a
prevalent vertebral fracture or hip T score below –2.5. The
clinical utility of various cut points in marker change was
also explored in order to predict fracture protection. A 30%
reduction in BSAP functions well in this respect and this is
an area for potential development as the range of available
markers expands and automated methodology improves
precision. In contrast, the change in spine BMD did not
predict fracture response and this was also true for hip BMD
except for the ability to predict reduction in spine fractures.
A new vertebral fracture causes considerable disability
with the main symptoms being back pain and kyphosis
leading to reduced mobility. Treatment would be expected
to reduce these complications by preventing new fractures
and an analysis of the vertebral fracture arm of FIT showed
that this appeared to be true. In this type of patient, back
problems are very common, but alendronate was able to
reduce the number of days that these osteoporotic women
spent on bed rest by 32% or with 7 or more days of limited
activity by 13%. This seemed due to the ability of the drug
to reduce the risk of new vertebral fractures (Nevitt et al
2000).
Compliance and duration of
treatment
Treatment of a chronic condition such as osteoporosis, where
symptoms are intermittent, is often accompanied by poor
compliance and anything which might improve this situation
is clearly an advantage. Bisphosphonates such as
alendronate strongly adsorb to hydroxyapatite and remain
active on the bone surface for several weeks during which
time osteoclastic bone resorption will be continuously
suppressed. In this way the effects of continuous daily
administration can be achieved by intermittent dosing with
the potential for improved compliance. In two studies
(Schnitzer et al 2000; Rizzoli et al 2002)
 it was shown that
administration of 70 mg of alendronate once weekly and
10 mg daily were equipotent in terms of the gain in BMD
and reduction in bone turnover. In a study of 1258
postmenopausal women, with a BMD T score below –2.5
or a prior vertebral or hip fracture, who were randomized toTherapeutics and Clinical Risk Management 2006:2(3) 241
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alendronate 70 mg once weekly (n=519), 35 mg twice
weekly (n=369) or 10 mg daily (n=370), the mean increase
in BMD at the lumbar spine at 24 months was 6.8%, 7.0%,
and 7.4% respectively. Similar equivalence of BMD gain
was seen at the femoral neck, trochanter, and total body.
Urine NTx , a marker of bone resorption, decreased by
comparison with baseline by 73.4%, 71.3%, and 74.9% in
the weekly, twice weekly, and daily groups while the
equivalent decreases in BSAP were 40.1%, 41.7%, and
43.1%. None of these changes were significantly different
between treatment groups. The reductions in NTx were
similar across treatment groups independent of baseline
BMD, bone turnover, years since menopause, or age. Upper
gastrointestinal adverse events occurred in 22.4%–23.8%
of patients in the one year study and in 29.0%–30.0% in the
two year study with no difference between treatment doses.
There was no placebo group in these studies and so the
incidence of upper gastrointestinal symptoms which might
be expected in this type of population is unknown.
Regulatory authorities require demonstration of
bioequivalence for the new formulation to claim the same
therapeutic efficacy on fracture protection as the formulation
against which this has actually been tested. Subsequent
experience has confirmed patient preference for weekly
treatment and the improvement in long term compliance
(McCombs et al 2004).
The prolonged adsorption of bisphosphonates to
calcified bone surfaces makes possible the shift from daily
to weekly therapy and this also influences the potential
duration of treatment. The original 3 year pivotal phase III
study (Liberman et al 1995) was extended out to ten years
(Bone et al 2004)
 with an interim analysis at 7 years (Tonino
et al 2000, 2001). At ten years, the effects on BMD and
bone turnover of 5 mg and 10 mg daily continuous treatment
with alendronate were compared with 20 mg for 2 years and
then 5mg daily for years 3–5 (discontinuation group).
Randomization and blinding were maintained out to 10 years
in the 247 women who remained in the study. Continuous
treatment with 5 mg and 10 mg daily resulted in a sustained
increase in BMD at all measurement sites (lumbar spine,
femoral neck, trochanter, total hip, and total body). The
major increase in BMD occurred in the first two years, but
there was a steady increase as long as therapy was continued.
These changes were consistent with filling in of the
resorption space early in treatment (Heaney et al 1997)
followed by more complete mineralization of the newly
formed bone as it ages (Boivin et al 2000). Lumbar spine
BMD increased by 13.7% after 10 years treatment with
10 mg daily but there were lesser gains at cortical sites, for
example, at the total body, which increased by only 3%.
BMD began to increase when treatment was discontinued,
but this was less marked at the spine compared with the
hip. This may just reflect the effect of age-related posterior
facet joint sclerosis offsetting losses of trabecular BMD from
the vertebral body. Urine NTx and BSAP remained
suppressed with continuous alendronate, but increased by
about 25% when treatment was discontinued although they
remained below baseline for the 5 years of observation
The effect of these changes on fracture rate are difficult
to assess since it is clearly unethical to have a placebo group
of osteoporotic women who remain untreated for a decade.
In this particular study, the effect of extended treatment was
estimated by adjusting the fracture rate in the placebo group
from the first three years of the study for the effects of
increasing age and extrapolating out to ten years. The
calculated and observed non-spine fracture rates were
similar, which appeared reassuring and was taken to indicate
that the effects of treatment were maintained. However it
must be recognized that the absolute number of fractures in
this residual cohort was small, which leads to an element of
clinical and statistical uncertainty. Morphometric fractures
were also recorded between years 6–10 in 228/247 women
and showed no significant difference between groups (10 mg
daily: 5%, 5 mg daily: 13.9%, discontinuation; 6.6%). There
was also no difference in height loss between the groups
which also suggests continuing benefit. These effects are
consistent with long term retention of alendronate in bone
which, although without effect when buried within bone,
retains biological activity when uncovered by osteoclastic
resorption. The practical implication of these observations
is that after 5 years treatment, there is the opportunity to
discuss the duration of treatment in the light of the published
evidence. A patient who has had no fractures while on
treatment may elect to discontinue treatment for a time
providing some form of biochemical or densitometric
monitoring is available to detect relapse. Patients who are
anxious about continuing fractures may prefer to continue
treatment and the 10 year study shows that this will maintain
control of bone turnover and maintain gains in BMD.
Similar conclusions were derived from the long term
extension of FIT (Ensrud et al 2004)
 where 1099 women
previously treated with alendronate were randomly assigned
to 5 mg or 10 mg of alendronate or placebo for a further 5
years. The women enrolled into this extension study were
slightly younger, had a higher increase in total hip BMD,
and were less likely to have had a new radiographic vertebralTherapeutics and Clinical Risk Management 2006:2(3) 242
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fracture compared with the women who were not enrolled
(commonly because of a desire to continue on open label
alendronate after completion of FIT). An interim analysis
at 3 years showed that further therapy with 5 mg–10 mg
of alendronate maintained BMD at the total hip, femoral
neck, and trochanter, leading to a difference from placebo
of about 2%, while at the lumbar spine this difference
was 2.5%.The gains in BMD were slightly greater with
the 10 mg dose (<1%) and reached statistical significance
at the hip, but not at the spine. The rate of decline in
BMD of the placebo group was similar to the background
rate observed in the first 3 years of FIT but did not show
“catch up” bone loss nor did this entirely erode the gains
made by earlier treatment. Bone turnover remained stable
and suppressed with both doses of alendronate. It
increased by around 20% in those given placebo, but was
still below baseline values after 3 years without therapy.
These findings are consistent with a residual effect due
to bisphosphonate retained within bone from earlier
treatment, but fracture rates were not assessed at this stage
and so the benefits from such prolonged treatment remain
uncertain until the study is completed.
All these studies were generally reassuring about the
long term use of alendronate.
A recent report of 9 cases who developed spontaneous
non-spine fractures while on alendronate therapy and who
showed delayed or absent fracture healing illustrates the
need for clinicians to be alert for such issues (Odvina et
al 2005). Iliac crest bone biopsies showed substantial
suppression of bone formation with absent double
tetracycline labeling, but less prominent reduction in
biochemical markers of bone turnover. Bone resorption
did not seem suppressed to the same degree but the
changes were seen in both cancellous and cortical bone.
All the patients were co-prescribed calcium and vitamin
D as is current practice but three were also receiving
estrogen and two prednisolone (one of whom also had
hypoparathyroidism), which may have contributed to the
picture. Fractures healed in most patients when
alendronate was discontinued. The risk of this situation
is unknown given the lack of a denominator and patients
in the pivotal clinical trials described earlier do develop
fractures while receiving alendronate and so a causal
relation cannot be made. The onset of spontaneous non-
spine fractures, particularly in unusual sites, should lead
to a review of treatment and an assessment of the
adequacy of fracture healing.
Comparison with other therapies
A major problem in the field of osteoporosis, and one which
is unlikely to be resolved, is the direct comparison between
drugs in terms of fracture end points. Even if there were
clinically significant differences of 5%–10% between drugs,
the size of such trials would be enormous, involving tens of
thousands of patients (Kanis et al 2002),
 making the cost
prohibitive. Comparisons can be made using surrogate
markers such as BMD or bone turnover although uncertainty
remains as to how differences might translate into fracture
protection (Hochberg et al 2002; Delmas and Seeman 2004;
Delmas et al 2004). Alendronate has been compared in this
way with risedronate and raloxifene and hormone
replacement therapy (HRT).
In a study of 1053 women with a low BMD (T score
below –2) who were randomized between weekly
alendronate (70 mg) and risedronate (35  mg) there were
greater gains after 12 months treatment in BMD at all
measurement sites with alendronate (Rosen et al 2005).
These differences were statistically significant (p<0.001
except femoral neck p<0.005) but modest (trochanter: 1.4%,
lumbar spine 1.2%, total hip: 1.0%, femoral neck: 0.7%).
There were also significantly greater reductions (p<0.001)
in bone turnover with alendronate (alendronate–risedronate
difference: urine NTx 12.6%, serum CTx 19.1%, BSAP
12.5%, PINP 15.9%). This study was also interesting since
it provided a direct comparison of the upper gut tolerability
of these two bisphosphonates and found no significant
difference. These effects on BMD, bone turnover, and
adverse event profile were similar to an earlier study which
compared weekly fasting alendronate with daily risedronate
given 2 hours after a main meal, which was the licence at
the time of the study for risedronate (Hosking et al 2003). It
was not clear whether the lesser efficacy of risedronate was
due to the daily between meal dosing or to an intrinsic
characteristic of the compound. The findings of the later
study are therefore more relevant since both agents are
currently predominantly administered in the once weekly
fasting formulation. It may be that where drugs have very
similar characteristics, then small differences, such as better
effects on BMD and bone turnover, have a substantial effect
on choice and this may partly explain the dominance of
alendronate in the treatment of postmenopausal
osteoporosis.
Raloxifene, the selective estrogen receptor modulator
(SERM) has a fundamentally different mode of action from
the bisphosphonates and two recent studies have comparedTherapeutics and Clinical Risk Management 2006:2(3) 243
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their effects on BMD and bone turnover (Luckey et al 2004;
Sambrook et al 2004). Both trials recruited post menopausal
women with low BMD (T score below –2.0) who were
randomized to 70 mg once weekly alendronate or 60 mg
daily raloxifene with appropriate placebo tablets to maintain
blinding. Both studies showed similar results with greater
increases in BMD and decreases in bone turnover with
alendronate. In the multinational trial (Sambrook et al 2004)
the mean gain in BMD with alendronate relative to
raloxifene was 2.6% at the lumbar spine, 2.0% at trochanter,
1.3% at femoral neck, and 1.6% at the total hip. None of
these differences were dependent on age or baseline BMD.
The reductions in bone turnover measured as urine NTx
and BSAP were approximately 40% greater with
alendronate. In the US study (Luckey et al 2004),
 the mean
gain in BMD with alendronate relative to raloxifene was
2.5% at the lumbar spine, 1.4% at trochanter, 0.3% at femoral
neck, and 1.0% at the total hip. Only the differences at the
lumbar spine, total hip, and trochanter reached statistical
significance. Differences in the degree of bone turnover
suppression in favor of alendronate were 45.5% for urine
NTx and 24.8% for BSAP. In both studies withdrawals
because of drug related or upper GI adverse events were
similar between the two drugs although a greater proportion
of patients reported vasomotor symptoms with raloxifene.
The use of alendronate and HRT in combination does
give some insight into the relative effects of these two agents.
In a group of postmenopausal women established on HRT
for at least a year (mean duration of therapy 9.7 years) the
addition of alendronate (10 mg daily) resulted in further
increments in BMD and decrements in bone turnover
(Lindsay et al 1999). The gains in BMD with the addition
of  alendronate  were  most  marked  at  the  lumbar  spine
(+2.6%) and hip trochanter (+2.2%), but did not reach
statistical significance at the femoral neck (+0.9%).These
changes were less than those seen in treatment naïve patients
due to the effects of the established HRT, but the study shows
the greater potency of this dose of alendronate and suggests
a clinical advantage of bisphosphonate in those women with
very low BMD.
Primary prevention
Although current clinical practice has moved away from
primary prevention for cost effectiveness reasons, there is
clear evidence that alendronate is able to reduce the bone
loss of recently postmenopausal women (Hosking et al 1998;
Ravn et al 1999). The Early Postmenopausal Intervention
Cohort (EPIC) study compared placebo with estrogen–
progestin and two doses of alendronate (2.5 mg and 5.0 mg
daily) in 1609 recently postmenopausal women aged 45–
59 years. Both doses of alendronate prevented the 4 year
2.9% decrease in BMD at the femoral neck seen in placebo-
treated women and produced a modest dose-related increase
of 0.6%–1.4%. Similar patterns of response were seen in
the subgroup of women with osteopenia as well as in the
total group at all measurement sites which included lumbar
spine, trochanter, total hip, total body, and distal one third
radius. The gain in BMD was greatest in women who were
further away from the onset of the menopause as is to be
expected from the observation that bone loss is most rapid
in the early menopausal years (Bjarnasson et al 2002).
Women treated with estradiol–norethisterone gained 3.7%
at the femoral neck while those given estrogen–
medroxyprogesterone acetate gained 1.8%. Both hormonal
treatments were also more effective than these low doses of
alendronate at the lumbar spine, total body, and forearm.
The switch from alendronate to placebo after 2 years in a
subset of women resulted in a resumption of bone loss at a
comparable rate seen in placebo-treated women at the
beginning of the study. Even so those women treated with
5 mg of alendronate were still above baseline at the hip and
spine with a more marked benefit compared with the
continuously treated placebo group. Bone turnover (NTx,
osteocalcin, and BSAP) decreased into the premenopausal
reference range with patterns of response consistent with
the changes in BMD. The study was not powered to show
an effect on fractures, which have a low frequency in this
early postmenopausal population (Doherty et al 2001).
Important differences between alendronate and hormone
treatment emerged when therapy was discontinued after 4
years (McClung et al 2004; Wasnich et al 2004). Women
treated continuously with alendronate for 6 years maintained
BMD at all measurement sites while those in whom
treatment was discontinued after four years lost bone at a
similar rate to placebo. In contrast the women treated with
hormonal therapy for 4 years had significantly greater mean
BMD losses at all sites during the 2 years after stopping
treatment than did those who had received alendronate 5 mg
for 4 years. BMD changes during the two years off hormone
or bisphosphonate treatment were, respectively: lumbar
spine (–7.69% and –2.42%), total hip (–5.16% and –1.09%),
femoral neck (–5.80% and –0.57%), trochanter (–7.22% and
–0.31%),  forearm  (–2.54%  and  –0.84%)  and  total  body
(–5.58% and –2.90%). The pattern of offset of treatment
effect on bone turnover was similar to that of BMD. TheseTherapeutics and Clinical Risk Management 2006:2(3) 244
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changes reflect the residual effect of bisphosphonate retained
in bone but the rapid loss of hormonal occupancy of
receptors.
Alendronate in the management
of male osteoporosis
Osteoporosis has up to recently been considered as a disease
that mainly affects women, and therefore most studies on
the treatment of osteoporosis has focused on female
osteoporosis. Age-related osteoporosis in men usually only
manifests at a later stage than in women (Usually >70 years
of age). Men that present with osteoporosis at a younger
age often have an underlying illness that increases bone loss
or decreases bone formation such as hypogonadism,
alcoholism, glucocorticoid treatment, anticonvulsant
therapy, and rheumatoid arthritis (Orwoll and Klein 2001).
Men are less likely to fall than women and have a lifetime
risk of osteoporotic fracture that is around one third of that
in women. The lifetime risk of a hip, spine,
 or forearm
fracture is 40%
 in white women and only 13%
 in white men
(Melton et al 1992, 1998). Although the major trials for
treatment of osteoporosis have mainly focused on
osteoporosis in females there have been several randomized,
controlled clinical studies that investigated the treatment of
osteoporosis in men.
Orwoll et al (2000) showed in a randomized controlled
study that alendronate given with calcium and vitamin D
was effective in the treatment of male osteoporosis. This
double blind, randomized study over a period of 2 years
compared the effect of daily alendronate 10 mg or placebo
on BMD in 241 men with osteoporosis. Thirty-seven of these
men were hypogonadal as evidenced by low free
testosterone concentrations with the rest having normal
testosterone concentrations. The age of the enrolled subjects
ranged between 31 and 87 years with a mean age of 63
years. Subjects were enrolled if they had a femoral neck T-
score of –2.0 SD or less and a lumbar spine T-score of –1.0
SD or less below the mean for a young healthy male. Male
subjects were also enrolled if they had a femoral neck T-
score of at least 1 SD below the young adult mean and at
least one vertebral deformity or a history of osteoporotic
fracture. All men with a secondary cause for osteoporosis
except hypogonadism were excluded from the trial.
The alendronate treatment group showed a mean increase
in BMD of 7.1% ± 0.3% at the lumbar spine, 2.5% ± 0.4%
at the femoral neck compared with an increase in the control
group of 1.8%±0.5% at the lumbar spine (p<0.001 for
comparison with baseline) and a reduction of –0.1% ± 0.5%
at the femur neck (insignificant difference). The increase in
the BMD in the alendronate group was significantly greater
than in the placebo group at all measurement sites (p<0.001).
There were similar increases in BMD in the hypogonadal
and the eugonadal men treated with alendronate. When
quantitative measurements were done for vertebral fractures,
the vertical fracture incidence was significantly lower in
the alendronate group than in the placebo group (0.8% vs
7.1%, p=0.02). There was no significant difference in the
rate of non-vertebral fractures between the placebo and
alendronate-treated groups (5.3% vs 4.1%, respectively).
The results conclusively show alendronate treatment is
beneficial in male patients with osteoporosis and also that
gonadal status does not influence
 the effect of alendronate
on BMD.
A further prospective study done by Ringe et al (2001)
confirmed the benefits of alendronate in the treatment of
male osteoporosis. This single centre, randomized
prospective 2-year study enrolled 134 men with established
primary osteoporosis. Any patient with hypogonadism or
other causes of secondary osteoporosis were excluded from
this study. No patient that was involved with this study had
any previous exposure to bisphosphonate treatment.
Subjects were randomized to receive either alendronate
(10 mg daily) or 1-alphacalcidol (1 µg daily) and all subjects
received an additional 500 mg per day of calcium
supplementation. None of the patients received any other
vitamin D replacement or other supplements.
Patients were seen at baseline and followed at 6, 12, 18,
and 24 months. Each visit included a physical examination
with height measurements. BMD of the lumbar spine and
femoral neck were done at baseline and were again repeated
at each follow up visit. X-rays of the spine were obtained at
baseline and this was repeated annually. Primary end points
of the study were to measure the change in lumbar spine
and femoral neck BMD over time. Secondary end points
included vertebral and non-vertebral fractures, and stature.
Lumbar spine density in the alendronate group increased
by 10.1% at year 2, and at the femur neck BMD increased
by 5.2%. The alphacalcidol group showed an increased
BMD of 2.8% at the lumbar spine and 2.2% at the femur
neck. P-values for the differences in the femur neck and
lumbar spine BMD in the two treatment groups were 0.001
and 0.009 respectively. The study showed that the total
number of new vertebral fractures was significantly reduced
in the alendronate treatment group (7.3% in alendronate
group vs 18.2% in alphacalcidol group, p=0.071). AlthoughTherapeutics and Clinical Risk Management 2006:2(3) 245
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the 1-alphacalcidol group showed a significant increase from
baseline in the lumbar spine BMD, these patients did not
have the same benefit with regards to new vertebral
fractures. There was no significant difference in the
incidence of non-vertebral fractures (8.7% in alendronate
group and 12.1% in the alphacalcidol group).
The results of this study were consistent with those
reported by Orwoll et al (2000) Both these studies confirmed
that men with established osteoporosis benefit from
treatment with alendronate and have an increased lumbar
spine and femoral neck BMD and also showed that
alendronate is generally well tolerated when used in a daily
format. The recommended dosage of alendronate for the
treatment of osteoporosis in men is 70 mg orally once weekly
or 10 mg orally once daily.
Alendronate and parathyroid
hormone in the treatment of
osteoporosis
Most therapies that are currently used for the management
of osteoporosis act mainly to inhibit bone resorption and
therefore reduce bone remodeling. Teriparatide, recombinant
human parathyroid hormone (PTH 1-34), was the first
anabolic bone agent for the treatment of osteoporosis
licensed for use in the US and the UK. It increases new
bone formation by increasing osteoblast differentiation,
osteoblast function, and survival. Teriparatide is
recommended for patients with severe osteoporosis and can
only be administered by once-daily injection in the thigh or
abdomen. The recommended dose is 20 mcg per day. The
maximum duration of use that is recommended is 18 months.
Parathyroid hormone is known to increase both bone
formation and bone absorption and treatment of osteoporosis
with PTH causes a marked increase in vertebral BMD.
However, this effect is rapidly reversed when the treatment
is stopped.
It was uncertain whether a combination of alendronate
and PTH would lead to an enhanced effect on bone and
also whether PTH treatment followed by alendronate would
preserve or increase bone density in patients previously
treated with PTH. The use of PTH in combination with
alendronate and also PTH followed by alendronate has been
investigated in several studies (Rittmaster et al 2000; Neer
et al 2001; Black et al 2003; Finkelstein et al 2003).
Finkelstein et al (2003) randomized 83 men between
the ages of 46–85 known to have low BMD into three
treatment groups. The men received alendronate 10 mg daily
(28 men), PTH 40 µg subcutaneously (27 men), or both (28
men). The subjects on alendronate only or combination of
PTH and alendronate were started on alendronate 10 mg
per day for a total of 30 months. PTH (1-84) was begun 6
months into the study and continued for a further 2 years.
BMD of the lumbar spine, proximal femur, radial shaft, and
total body was measured every 6 months using a dual energy
x-ray absorbed geometry and densitometry scanner. For the
radial shaft two measurements were obtained at each visit,
and the mean of the two values were used in analysis. BMD
of the lumbar spine in the posterior anterior and lateral
projections and the proximal femur as well as the distal one
third of the radial shaft was measured. The study also
included measuring trabecular BMD of the lumbar spine
using computer tomography.
The results of the study confirmed what was already
known about the administration of alendronate as a single
agent. On the posterior-anterior spine, there was a mean
increase in BMD of 7.9% and of the lateral spine 11.1%.
Femur neck density increased by 3.2% with a total hip
density increasing by 4.8%. The PTH group had a clinically
significant mean percentage increase in BMD of 18.1%,
25.8%, 9.7%, and 6.4% at the posterior-anterior spine, lateral
spine, femoral neck, and total hip respectively. The
theoretical benefit from a combination of an anabolic bone
agent (teriparatide) and an inhibitor of bone resorption
(alendronate) did not seem to have any advantage. In the
combination therapy group, the mean increase in BMD was
almost midway between the alendronate-only group at the
lower end of the scale and the PTH group only at the higher
end of the scale. The mean percent increase in BMD in the
combination group was 14.8%, 18.0%, 6.2%, and 5.3% at
the posterior-anterior spine, lateral spine, femoral neck, and
total hip respectively. The lumbar spine effects of the
combination of alendronate and teriparatide were no better
than either agent alone, where as the total hip combination
was no different from that of the alendronate alone. The
study suggested that alendronate significantly impairs the
anabolic effect of teriparatide, especially if patients have
been pre-treated with alendronate.
Black et al (2003) conducted a similar study in 238
women with a T-score of less than –2.5 for BMD at
 the
femoral neck, total hip, or spine. They also included women
with a T-score
 of less than –2.0 at one of the above sites, but
who also had a further risk factor (age ≥65 years, a
 history
of postmenopausal fracture and a maternal history of hip
fracture. The women were randomly assigned to one of three
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later extended to 2 years – see below). Women were assigned
to take PTH
 plus placebo (n=119), PTH plus alendronate
(n=59), and alendronate plus placebo (n=60). All the subjects
received a daily dose of calcium and
 vitamin D supplement.
BMD
 was measured at the femoral neck and total hip
regions,
 the postero-anterior lumbar spine (L1 to L4), and
also at the distal one third of the radial shaft. Measurements
were done at baseline and again at 12 months.
The results showed that BMD increased in all the women
receiving treatment and there were no significant difference
between the PTH monotherapy and the PTH–alendronate
combination group. The areal BMD of the lumbar spine
increased by 6.3% in the PTH monotherapy group and by
6.1% in the PTH–alendronate combination group. The
femoral neck and total hip BMD remained essentially
unchanged in the PTH monotherapy group but there was a
significantly greater increase in total hip BMD in the PTH–
alendronate combination group (0.3% vs. 1.9%). There was
also an increase of the femoral neck and total hip BMD in
the alendronate monotherapy group. The distal radius BMD
decreased
 significantly in the PTH group (–3.4%), but results
showed that treatment with alendronate might decrease the
rate of bone loss. BMD loss in PTH–alendronate group was
–1.1% with similar loss in the alendronate monotherapy
group.
One of the great strengths of PTH is the significant
increase in vertebral BMD, but PTH is currently not licensed
for long-term maintenance treatment of osteoporosis. An
attractive alternative theory emerged whereby the benefit
of PTH on bone remodeling could be maintained after
withdrawal of PTH by treating a patient with an
antiresorptive agent such as alendronate. Rittmaster et al
(2000) conducted a study to determine whether alendronate
would prevent bone loss or even enhance BMD in patients
previously treated with PTH. Postmenopausal women
(n=66) with a diagnosis of osteoporosis were treated for 1
year with either recombinant PTH (1-84) using the doses
50 mcg, 75 mcg, or 100 mcg or were given placebo. Note
that the dose of PTH (1-84) differs from that of teriparatide
(PTH 1-34). All subjects were then were given a daily dose
of alendronate 10 mg daily for an additional year. Femoral
neck, lumbar spine, and whole body BMD was measured.
During the first year of the study, changes in BMD (mean ±
SD) in women receiving PTH (all doses combined) were
7.1%±5.6%  (spine),  0.3%±6.2%  (femoral  neck),  and
–2.3%±3.3% (total body). After withdrawal of PTH and
starting on alendronate for the next year in the women who
had received PTH, the mean changes in BMD were
13.4%±6.4% (spine), 4.4%±7.2% (femoral neck), and
2.6%±3.1% (whole body). This study showed that sequential
treatment of osteoporotic patients with PTH followed by
alendronate results in a further increase in vertebral BMD
that is significantly higher than BMD gained with PTH only
and also with simultaneous alendronate and PTH.
In a recent extension of the study by Black et al
(2003), the investigators reported on the question of
whether PTH treatment should be followed by
antiresorptive therapy such as alendronate (Black et al
2005). Women who had received PTH (1-84)
monotherapy 100 µg per day, in the first year were then
randomized to receive either alendronate (n=59) or
placebo (n=60) for an additional year. The study also
extended the treatment of subjects who had received a
combination of alendronate and PTH in year one, to
continue these patients with alendronate only in the
second year of the study. Those subjects who had received
alendronate monotherapy in the first year, continued with
the same therapy during year two. Changes in BMD at
the hip and spine was assessed as before through the use
of DEXA scanning and quantitative computer
tomography (CT).
The results of the study showed that in the women who
received PTH for 12 months followed by alendronate 10 mg
daily for a further 12 months, there was a significant
additional increase in BMD at the spine (4.9%, p<0.001)
and also a significant increase in BMD at the hip (3.6%
p<0.001).
The women, who had received PTH for the first 12
months of this study and was followed by placebo treatment
for a further 12 months, had a significant decrease in BMD
at the spine (–1.7%, p=0.002) with no significant change in
bone density at the hip or radius. The difference in BMD
gain in year two between PTH–alendronate group and bone
loss in the PTH–placebo group was shown to be significant
at the spine and the total hip.
At the time of the study, teriparatide had only been
recently approved for use in osteoporosis and it was not
clear whether there would be any benefit in combining
teriparatide with an antiresorptive drug such as alendronate.
The trial was designed to investigate what effect different
combinations would have on BMD at the spine and femur
neck. It was shown that using PTH (1-84) in combination
with alendronate did not provide any clear benefit over PTH
only. This study confirmed the findings of previous reports
that alendronate therapy following PTH leads to further
increase in BMD and is likely to protect against increasedTherapeutics and Clinical Risk Management 2006:2(3) 247
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bone resorption following withdrawal of PTH (Lindsay et
al 1997; Rittmaster et al 2000; Kurland et al 2004; Lindsay
et al 2004).
Alendronate in corticosteroid-
induced osteoporosis
Glucocorticoids are widely used to treat a number of major
illnesses such as chronic obstructive pulmonary disease,
inflammatory bowel disease, and other inflammatory
diseases such as rheumatoid arthritis and polymyalgia
rheumatica. Corticosteroids are also commonly used for
immunosuppression in transplant recipients and also in the
management of certain hematological malignancies (Walsh
et al 1996).
The benefit of glucocorticoid treatment has to be
weighed up against the numerous side effects that the users
suffer. One of the long-term side effects of glucocorticoid
use is the development of osteoporosis. The administration
of oral glucocorticoids is associated with a significant
increase in fracture risk at the hip and spine. The greatest
increase in osteoporosis risk is associated with intake of
high doses of glucocorticoids, however an increased risk is
seen with daily administration of prednisolone at doses lower
than 7.5 mg. The risk for osteoporotic fractures also increases
after initiating glucocorticoid treatment, but this declines
soon after stopping treatment (Van Staa et al 2000, 2002).
Corticosteroid-induced osteoporosis results from the
effect of corticosteroids on bone and calcium homeostasis.
Direct effects of steroids include the suppression of intestinal
calcium absorption with increases to urinary, calcium, and
phosphate loss. Steroids lead to a suppression of osteoblast
precursor formation with increased apoptosis of mature
osteoblasts. Glucocorticoid treatment inhibits synthesis
 and
secretion of bone matrix proteins, growth factors, and
cytokines and reduces androgen secretion. Furthermore it
leads to an increase in osteoclast formation leading to net a
reduction in bone formation and increased resorption. It is
thought that a reduction of calcium and phosphate absorption
from the gut and increased renal losses, may lead to low-
grade secondary hyperparathyroidism with further increased
osteoclast activity (Cosman et al 1994; Patschan et al 2001;
Weinstein 2001; Canalis et al 2004)
Several studies investigated the efficiency of alendronate
for the prevention and treatment of glucocorticoid-induced
osteoporosis. Gonnelli et al (1997) demonstrated the
effectiveness of alendronate in preventing osteoporosis in
patients with sarcoid treated with glucocorticoid drugs.
Forty-three patients with sarcoid (17 men and 26 pre-
menopausal women) were included in the study. Thirteen
of these patients did not need any glucocorticoid treatment
and served as controls. The remaining 30 patients that
needed glucocorticoid therapy were randomized to receive
either placebo or alendronate 5 mg per day. BMD was
measured at the ultra-distal radius and biochemical markers
of bone turnover were measured at baseline and after 6 and
12 months of glucocorticoid therapy. The glucocorticoid
dose was not significantly different between the placebo
and alendronate group. The alendronate-treated group’s
BMD increased by 0.8% and the BMD in the placebo group
decreased by 4.5% (p<0.01) There was a significant decrease
in markers of bone formation in all patients on
glucocorticoids, however, the alendronate-treated group had
a reduction in the biochemical markers of bone resorption
compared with the placebo group. This relatively small study
confirmed that alendronate is effective in preventing
glucocorticoid-induced bone loss.
Saag et al (1998) carried out two 48 week randomized,
placebo-controlled studies on the use of alendronate in male
and female patients (17–83 years of age). Investigators
enrolled 477 men and women with underlying pulmonary,
rheumatological, dermatological, gastrointestinal, or other
diseases that required long-term oral glucocorticoid
treatment at a dose of at least 7.5 mg per day. The first multi-
center study enrolled 232 patients in the US and the second
multi-center study enrolled 328 patients in 15 other
countries. Patients were randomly signed to receive 2.5 mg,
5 mg, or 10 mg of oral alendronate or a matching placebo.
All patients in both the studies were treated for a minimal
of 48 weeks. Subjects received daily supplements of calcium
and vitamin D. Subjects were stratified for the duration of
the glucocorticoid use in three groups (<4 months, 4–12
months, and >12 months). Mean daily dose of glucocorticoid
use was 10mg of prednisolone (or equivalent). BMD of the
lumbar spine and hip as well as the total body BMD was
measured at baseline and again at 12, 24, and 48 weeks by
dual energy x-ray absorptiometry (DEXA scan). At the same
time serum and urine samples were obtained for baseline
measurement of markers of bone turnover (serum BSAP
and urinary excretion of cross-linked n-terminal telopeptides
of type 1 collagen).
The investigators reported that alendronate significantly
increased lumbar spine and hip BMD in the 5 mg and 10 mg
alendronate groups. The lumbar spine BMD was increased
by 2.1% and 2.9% with femur neck BMD increased by 1.2%
and 1.0% in the 5 mg and 10 mg alendronate groupsTherapeutics and Clinical Risk Management 2006:2(3) 248
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respectively. The placebo group had minimal bone loss
at the lumbar spine of –0.4% and a reduction of BMD at
the femur neck of –1.2%. There was a reduction in
markers of bone resorption and formation in both the 5 mg
and 10 mg alendronate groups. This study showed that
alendronate significantly increases BMD in patients with
glucocorticoid-induced osteoporosis and patients who are
at high risk of developing osteoporosis on glucocorticoid
treatment. The benefit of alendronate therapy was seen
in men, pre-menopausal women, and post-menopausal
women whether or not they were receiving HRT at the
time. The vertebral fracture rate was reduced by
approximately 50% in the alendronate treatment group
although this was only statistically significant among the
post-menopausal women; the reason for this is probably
because the younger patients were at lower risk of
vertebral fractures anyway.
A 12-month extension of the above study (Saag et al
1998) was reported in 2001 (Adachi et al 2001). This showed
that all patients receiving alendronate had a further increase
in lumbar spine and trochanter BMD in the 12-month
extension period, while maintaining the BMD at the femoral
neck. Patients receiving placebo continued to lose bone in
the extension period at all sites. Alendronate therapy (5mg,
10 mg, or 2.5/10 mg daily) to a total of two years increased
lumbar spine BMD by between 2.8% and 3.9%, a significant
improvement compared with placebo (0.8% decrease).
Incidents of vertebral fractures were reduced in the
alendronate group versus the placebo group (0.7% vs 6.8%
respectively).
According to the above studies, alendronate has been
shown to be effective at increasing BMD of the spine and
total hip and also reduces vertebral fractures in patients on
long-term glucocorticoid therapy. Following on from these
studies, routine BMD testing and early treatment with
bisphosphonates have been recommended by several groups
such as the Royal College of Physicians of London and the
American College of Rheumatology Ad Hoc Committee on
Glucocorticoid-Induced Osteoporosis.
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